Enanta Pharmaceuticals Inc (ENTA) 38.82 $ENTA
AcelRx Pharmaceuticals (ACRX) Soars: Stock Adds 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 8:39AM CDT
AcelRx Pharmaceuticals, Inc. (ACRX) was a big mover last session, as its shares rose nearly 7% on the day.
TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:10PM CDT
TESARO (TSRO) reported second-quarter loss of $1.00 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents and year-ago loss of 67 cents.
Pharmacyclics (PCYC) Jumps: Stock Rises 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 8:39AM CDT
Pharmacyclics Inc. (PCYC) was a big mover last session, as its shares rose roughly 15% on the day.
QLT Inc. (QLTI) Soars: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:51AM CDT
QLT Inc. (QLTI) was a big mover last session, as its shares rose nearly 8% on the day.
Enanta Pharmaceuticals, Inc. - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:21AM CDT
Summary
AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:39AM CDT
AcelRx Pharmaceuticals, Inc. (ACRX) was a big mover last session, as its shares rose nearly 12% on the day.
ImmunoGen (IMGN) Soars: Stock Up 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:51AM CDT
ImmunoGen, Inc. (IMGN) was a big mover last session, as its shares rose nearly 9% on the day.
Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
at The Street - Fri Jul 18, 6:51AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Merck, Gilead Lead Race To Eradicate Hepatitis C
at Investor's Business Daily - Thu Jul 03, 4:08PM CDT
Even if you're not a biotech or pharma investor, you've probably caught an earful of news lately about the virus called hepatitis C. From last December's record-breaking launch of Gilead Sciences' (GILD) wonder drug Sovaldi to the controversies about...
Patent Issuance, Positive Trial Data, Recognitions, and Priority Review - Analyst Notes on Keryx, Puma, Ligand, Sagent and Enanta
PR Newswire - Mon Jun 30, 6:50AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Puma Biotechnology, Inc. (NYSE: PBYI), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4240-100free.
Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding
Is This Gilead's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
It's not often that big name biotechs double their earnings year over year. Yet that's exactly what Gilead Sciences did in the first quarter of 2014 after posting record sales for its new hepatitis C drug Sovaldi. Sovaldi raked in a reported...
European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire Europe - Tue Jun 17, 4:19AM CDT
AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA).
Enanta Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C
Business Wire - Tue Jun 17, 1:03AM CDT
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that AbbVie has reported that the Marketing Authorization Applications (MAAs) for AbbVie's investigational, all-oral, interferon-free regimen primarily for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been fully validated and are now under accelerated assessment by the European Medicines Agency (EMA).
Why Shorts Are Betting Against Enanta Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Sun Jun 15, 5:00PM CDT
Short interest is often a key metric that investors can use to gain some insight into how the Street feels about a particular stock. And when short interest picks up dramatically, it's generally a good idea to know why. Shares of little-known ...
Enanta Pharmaceuticals Announces U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C
Business Wire - Fri Jun 13, 2:39PM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the New Drug Application (NDA) for AbbVie's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review.
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire - Fri Jun 13, 2:34PM CDT
AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review.
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d8sbsp/vancomycinresista) has announced the addition of the "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Exploit Technologies Pte Ltd - Piramal Enterprises Limited - Aphios Corporation - Wockhardt Limited - Paratek Pharmaceuticals, Inc. - Alchemia Limited - Immtech Pharmaceuticals, Inc. - Lorus Therapeutics Inc. - NovaBay Pharmaceuticals, Inc. - Oragenics, Inc. - Microbio Co., Ltd. - MicuRx Pharmaceuticals, Inc. - Enanta Pharmaceuticals, Inc. - TAXIS Pharmaceuticals, Inc. - LegoChem Biosciences, Inc - MGB Biopharma Limited - Sentinella Pharmaceuticals, Inc. - Sealife PHARMA GMBH For more information visit http://www.researchandmarkets.com/research/d8...cinresista
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
Business Wire - Tue Jun 10, 3:05PM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview on Tuesday, June 17, 2014, at 4:05 p.m. ET during the Wells Fargo 2014 Healthcare Conference in Boston and on Wednesday, June 25, 2014 at 10:30 a.m. ET during the JMP Securities 9th Annual Healthcare Conference in New York.
AcelRx Pharmaceuticals (ACRX) Soars: Stock Adds 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 8:39AM CDT
AcelRx Pharmaceuticals, Inc. (ACRX) was a big mover last session, as its shares rose nearly 7% on the day.
TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 2:10PM CDT
TESARO (TSRO) reported second-quarter loss of $1.00 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents and year-ago loss of 67 cents.
Pharmacyclics (PCYC) Jumps: Stock Rises 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 8:39AM CDT
Pharmacyclics Inc. (PCYC) was a big mover last session, as its shares rose roughly 15% on the day.
QLT Inc. (QLTI) Soars: Stock Adds 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 7:51AM CDT
QLT Inc. (QLTI) was a big mover last session, as its shares rose nearly 8% on the day.
Enanta Pharmaceuticals, Inc. - Product Pipeline Review - 2014
M2 - Fri Jul 25, 3:21AM CDT
Summary
AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:39AM CDT
AcelRx Pharmaceuticals, Inc. (ACRX) was a big mover last session, as its shares rose nearly 12% on the day.
ImmunoGen (IMGN) Soars: Stock Up 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:51AM CDT
ImmunoGen, Inc. (IMGN) was a big mover last session, as its shares rose nearly 9% on the day.
Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
at The Street - Fri Jul 18, 6:51AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Merck, Gilead Lead Race To Eradicate Hepatitis C
at Investor's Business Daily - Thu Jul 03, 4:08PM CDT
Even if you're not a biotech or pharma investor, you've probably caught an earful of news lately about the virus called hepatitis C. From last December's record-breaking launch of Gilead Sciences' (GILD) wonder drug Sovaldi to the controversies about...
Patent Issuance, Positive Trial Data, Recognitions, and Priority Review - Analyst Notes on Keryx, Puma, Ligand, Sagent and Enanta
PR Newswire - Mon Jun 30, 6:50AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Puma Biotechnology, Inc. (NYSE: PBYI), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4240-100free.
Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding
Is This Gilead's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
It's not often that big name biotechs double their earnings year over year. Yet that's exactly what Gilead Sciences did in the first quarter of 2014 after posting record sales for its new hepatitis C drug Sovaldi. Sovaldi raked in a reported...
European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire Europe - Tue Jun 17, 4:19AM CDT
AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA).
Enanta Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C
Business Wire - Tue Jun 17, 1:03AM CDT
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that AbbVie has reported that the Marketing Authorization Applications (MAAs) for AbbVie's investigational, all-oral, interferon-free regimen primarily for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been fully validated and are now under accelerated assessment by the European Medicines Agency (EMA).
Why Shorts Are Betting Against Enanta Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Sun Jun 15, 5:00PM CDT
Short interest is often a key metric that investors can use to gain some insight into how the Street feels about a particular stock. And when short interest picks up dramatically, it's generally a good idea to know why. Shares of little-known ...
Enanta Pharmaceuticals Announces U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C
Business Wire - Fri Jun 13, 2:39PM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that the New Drug Application (NDA) for AbbVie's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review.
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire - Fri Jun 13, 2:34PM CDT
AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review.
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d8sbsp/vancomycinresista) has announced the addition of the "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Exploit Technologies Pte Ltd - Piramal Enterprises Limited - Aphios Corporation - Wockhardt Limited - Paratek Pharmaceuticals, Inc. - Alchemia Limited - Immtech Pharmaceuticals, Inc. - Lorus Therapeutics Inc. - NovaBay Pharmaceuticals, Inc. - Oragenics, Inc. - Microbio Co., Ltd. - MicuRx Pharmaceuticals, Inc. - Enanta Pharmaceuticals, Inc. - TAXIS Pharmaceuticals, Inc. - LegoChem Biosciences, Inc - MGB Biopharma Limited - Sentinella Pharmaceuticals, Inc. - Sealife PHARMA GMBH For more information visit http://www.researchandmarkets.com/research/d8...cinresista
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
Business Wire - Tue Jun 10, 3:05PM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview on Tuesday, June 17, 2014, at 4:05 p.m. ET during the Wells Fargo 2014 Healthcare Conference in Boston and on Wednesday, June 25, 2014 at 10:30 a.m. ET during the JMP Securities 9th Annual Healthcare Conference in New York.
